Switch to: References

Add citations

You must login to add citations.
  1. Withholding and Withdrawing Life-Sustaining Treatment: Ethically Equivalent?Lars Øystein Ursin - 2019 - American Journal of Bioethics 19 (3):10-20.
    Withholding and withdrawing treatment are widely regarded as ethically equivalent in medical guidelines and ethics literature. Health care personnel, however, widely perceive moral differences between withholding and withdrawing. The proponents of equivalence argue that any perceived difference can be explained in terms of cognitive biases and flawed reasoning. Thus, policymakers should clear away any resistance to accept the equivalence stance by moral education. To embark on such a campaign of changing attitudes, we need to be convinced that the ethical analysis (...)
    Download  
     
    Export citation  
     
    Bookmark   30 citations  
  • A Morally Permissible Moral Mistake? Reinterpreting a Thought Experiment as Proof of Concept.Nathan Emmerich & Bert Gordjin - 2018 - Journal of Bioethical Inquiry 15 (2):269-278.
    This paper takes the philosophical notion of suberogatory acts or morally permissible moral mistakes and, via a reinterpretation of a thought experiment from the medical ethics literature, offers an initial demonstration of their relevance to the field of medical ethics. That is, at least in regards to this case, we demonstrate that the concept of morally permissible moral mistakes has a bearing on medical decision-making. We therefore suggest that these concepts may have broader importance for the discourse on medical ethics (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  • Formulating an Ethics of Pharmaceutical Disinvestment.Jessica Pace, Tracey-Lea Laba, Marie-Paul Nisingizwe & Wendy Lipworth - 2020 - Journal of Bioethical Inquiry 17 (1):75-86.
    There is growing interest among pharmaceutical policymakers in how to “disinvest” from subsidized medicines. This is due to both the rapidly rising costs of healthcare and the increasing use of accelerated and conditional reimbursement pathways which mean that medicines are being subsidized on the basis of less robust evidence of safety and efficacy. It is crucial that disinvestment decisions are morally sound and socially legitimate, but there is currently no framework to facilitate this. We therefore reviewed the bioethics literature in (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation